Trump The threat of the pharmaceutical rate decreases after the Pfizer agreement
The president of the United States, Donald Trump, shakes hand with the Pfizer CEO, Albert Bourla (L), while announcing an…
Gilead Sciences Inc.
Trump asks drug manufacturers to reduce prices in 60 days
The president of the United States, Donald Trump, the Secretary of Human Services and Health of the United States (HHS),…
Novartis, Roche could be at greater risk
The medications are stored on shelves on a pharmacy on May 12, 2025 in Los Angeles, California. Eric Thayer |…
Medicaid's cuts in Trump's Megabill will hit some drug manufacturers
The president of the United States, Donald Trump, presents a broad legislation of expenses and prosecutors, known as the “Law…
The FDA approves the HIV prevention injection of Gilead Lenacapavir
Food and medication administration approved Wednesday Gilead 'S Antiviral injection twice a year to prevent HIV, a milestone that the…
The best selections of Biotechnology and Farma by JPMorgan for the second half
The low performance of biopharmaceutical actions versus the widest market for a third consecutive year is an opportunity for investors,…
Astrazeneca, Pfizer, Gilead releases cancer medicines data
Attendees walk through the lobby of the annual meeting of the American Society of Clinical Oncology in Chicago. Tim Boyle…
Trump tariffs will challenge the big pharmaceuticals. Here are well positioned actions
Long Data Commercial Agreements have greatly protected the pharmaceutical industry of tariffs, but the objective of President Donald Trump to…
China Biopharma agreements increase with Summit, Merck
A little -known biotechnology company surprised the biopharmaceutical industry last spring when he declared an “unprecedented” achievement: his experimental medication…
Innovative biotech stocks have a good chance of breaking out in 2025
The trends may be turning in favor of biotech stocks in 2025 after several years of poor performance, but it…